Designer Functional Foods on Parameters of Metabolic and Vascular in Prediabetes

NCT ID: NCT02400450

Last Updated: 2017-02-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2016-09-30

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multi-site, double-blind, randomized, controlled food intervention study being conducted at the Canadian Centre for Agri-Food Research in Health and Medicine (CCARM) in Winnipeg and the Mayo Clinic, Rochester, MN, to examine the effects of a portfolio of functional foods on blood glucose and lipids, and blood vessel function in individuals with prediabetes.

A total of 116 participants (n=58/site) with prediabetes (hemoglobin A1c ≥6.0 \& \<7.0 and no glucose-lowering medications) and body-mass index (BMI) 18-40 will be recruited for a 12-week clinical trial to determine the effect of eating 2 items containing functional ingredients daily compared to 2 similar items lacking the functional ingredients. Study foods provided are to be incorporated into participant's usual diet.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will investigate the effect of a 12 week intervention with a portfolio of 7 food products and 7 comparator products for their effect on glycated hemoglobin, blood lipids, blood vessel function and metabolic parameters in persons with prediabetes. Prediabetes precedes the manifestation of type 2 diabetes and is therefore an appropriate target for dietary interventions. It is also associated with increased cardiovascular disease (CVD) risk because of the presence of abdominal obesity, elevated LDL-cholesterol and reduced vascular function. CVD risk will be assessed based on the profile of lipids and other factors in the blood as well using specialized equipment for non-invasive monitoring of blood vessel function.

If the foods prove beneficial for managing blood glucose levels, the publication of results in scientific journals and in lay documents will increase awareness and provide important information of the health benefits of these products for consumers, health professionals and the food industry. It will also help individuals who may be able to manage their illnesses in a healthful non-pharmaceutical nutritional approach and who may benefit from physician-prescribed nutritional counseling with a focus on foods known to improve certain disease biomarkers. At this time these approaches lack practicality and direct application to individuals who are interested in adopting a new dietary regime capable of disease prevention.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pre-Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Functional Ingredient Group

Participants will be provided with a mix of 6 study products to use over the 12 week trial (2 per day). These will be a) oatmeal, b) pancake mix, c) chocolate crunch bar, d) cranberry nut bar, e) anytime sprinkle, and f) smoothie mix. The food items will contain a standardized amount of functional ingredients.

Group Type EXPERIMENTAL

Functional Ingredient Group

Intervention Type DIETARY_SUPPLEMENT

Participants will be provided with a mix of 6 study products to use over the 12 week trial (2 per day). These will be a) oatmeal, b) pancake mix, c) chocolate crunch bar, d) cranberry nut bar, e) anytime sprinkle, and f) smoothie mix, standardized for the content of functional ingredients.

Control Ingredient Group

The control group will receive a comparable set of food items that contain an equivalent amount of calories per portion but without the added functional ingredients.

Group Type PLACEBO_COMPARATOR

Control Ingredient Group

Intervention Type DIETARY_SUPPLEMENT

The control group will receive a comparable set of food items to use over the 12 week trial (2 per day). These food items will contain an equivalent amount of calories per portion but without the additional functional ingredients.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Functional Ingredient Group

Participants will be provided with a mix of 6 study products to use over the 12 week trial (2 per day). These will be a) oatmeal, b) pancake mix, c) chocolate crunch bar, d) cranberry nut bar, e) anytime sprinkle, and f) smoothie mix, standardized for the content of functional ingredients.

Intervention Type DIETARY_SUPPLEMENT

Control Ingredient Group

The control group will receive a comparable set of food items to use over the 12 week trial (2 per day). These food items will contain an equivalent amount of calories per portion but without the additional functional ingredients.

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Step One Foods (TruHealthMD)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Participants must meet the following criteria to be eligible for participation in the study:

1. Male, or non-pregnant, non-lactating females, aged 21 - 75 years;
2. Glycated hemoglobin A1c ≥6.0% and \<7.0%;
3. Body-mass index 18-40;
4. Able to read, write and communicate orally in English;
5. Willing to maintain a stable level of activity during participation in the study;
6. Willing to comply with protocol requirements and procedures;
7. Willing to provide written informed consent.

Exclusion Criteria

Failure to meet any one of the above eligibility criteria will result in an inability to participate in the study. Participants will also be excluded if they have or require any of the following:

1 Previous diagnosis of diabetes or taking diabetes medications (glucose-lowering medications, insulin);

2\. Previous diagnosis of cardiovascular disease (e.g. heart attack, stroke, peripheral artery disease), or taking lipid-lowering medications, or having a surgical procedure/intervention to treat cardiovascular disease (e.g. bypass surgery, stent). \[Note that individuals with hypertension and/or taking anti-hypertensive medication are eligible to participate.\];

3\. Fasting LDL-cholesterol \>160 mg/dL (\>4.1 mmol/L);

4\. Fasting triglycerides \>400 mg/dL (\>4.5 mmol/L);

5\. Serum alanine aminotransferase (ALT) outside the normal range of 7-56 units/L;

6\. Serum creatinine outside the normal range of 0.7-1.3 mg/dL for males and 0.6-1.1 mg/dL for females;

7\. Conditions which affect normal nutrient absorption (e.g. Celiac disease, inflammatory bowel disease);

8\. Untreated endocrine disorders with the potential to affect glucose and lipid metabolism;

9\. In the previous 3 months and during the study, consumption of supplements or herbals in amounts that lower blood glucose or blood lipids (e.g. chromium, margarine with plant sterols, high fibre supplements such as Metamucil, cinnamon extract, ginseng, bitter melon, gamma-linolenic acid);

10\. Food allergies or intolerances which severely limit the variety of study food products that can be consumed;

11\. Eating philosophies or eating patterns that would limit or not include consumption of the study foods;

12\. Any acute medical condition or surgical intervention within the past 3 months;

13\. Conditions or medications which are likely to increase the risk to the participants or study personnel, or to reduce the ability of the participant to comply with the protocol, or affect the results;

14\. Currently participating in or having participated in a food intervention study within the last month;

15\. Inability to adhere to the study protocol;

16\. Unable to obtain blood sample at the screening and/or baseline visit.
Minimum Eligible Age

21 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Manitoba Science and Technology International Collaboration Fund

UNKNOWN

Sponsor Role collaborator

Manitoba Agri-Health Research Network

OTHER

Sponsor Role collaborator

University of Manitoba

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr. Carla Taylor

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Carla Taylor, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Manitoba

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mayo Clinic

Rochester, Minnesota, United States

Site Status

St. Boniface General Hospital

Winnipeg, Manitoba, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

References

Explore related publications, articles, or registry entries linked to this study.

Lindstrom J, Louheranta A, Mannelin M, Rastas M, Salminen V, Eriksson J, Uusitupa M, Tuomilehto J; Finnish Diabetes Prevention Study Group. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care. 2003 Dec;26(12):3230-6. doi: 10.2337/diacare.26.12.3230.

Reference Type BACKGROUND
PMID: 14633807 (View on PubMed)

Diabetes Prevention Program Research Group; Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009 Nov 14;374(9702):1677-86. doi: 10.1016/S0140-6736(09)61457-4. Epub 2009 Oct 29.

Reference Type BACKGROUND
PMID: 19878986 (View on PubMed)

Silva FM, Kramer CK, de Almeida JC, Steemburgo T, Gross JL, Azevedo MJ. Fiber intake and glycemic control in patients with type 2 diabetes mellitus: a systematic review with meta-analysis of randomized controlled trials. Nutr Rev. 2013 Dec;71(12):790-801. doi: 10.1111/nure.12076. Epub 2013 Nov 1.

Reference Type BACKGROUND
PMID: 24180564 (View on PubMed)

Hlebowicz J, Drake I, Gullberg B, Sonestedt E, Wallstrom P, Persson M, Nilsson J, Hedblad B, Wirfalt E. A high diet quality is associated with lower incidence of cardiovascular events in the Malmo diet and cancer cohort. PLoS One. 2013 Aug 5;8(8):e71095. doi: 10.1371/journal.pone.0071095. Print 2013.

Reference Type BACKGROUND
PMID: 23940694 (View on PubMed)

Deng R. A review of the hypoglycemic effects of five commonly used herbal food supplements. Recent Pat Food Nutr Agric. 2012 Apr 1;4(1):50-60. doi: 10.2174/2212798411204010050.

Reference Type BACKGROUND
PMID: 22329631 (View on PubMed)

Lee T, Dugoua JJ. Nutritional supplements and their effect on glucose control. Adv Exp Med Biol. 2012;771:381-95. doi: 10.1007/978-1-4614-5441-0_27.

Reference Type BACKGROUND
PMID: 23393691 (View on PubMed)

Shane-McWhorter L. Dietary supplements and probiotics for diabetes. Am J Nurs. 2012 Jul;112(7):47-53. doi: 10.1097/01.NAJ.0000415961.92674.d4.

Reference Type BACKGROUND
PMID: 22739611 (View on PubMed)

Suksomboon N, Poolsup N, Boonkaew S, Suthisisang CC. Meta-analysis of the effect of herbal supplement on glycemic control in type 2 diabetes. J Ethnopharmacol. 2011 Oct 11;137(3):1328-33. doi: 10.1016/j.jep.2011.07.059. Epub 2011 Aug 5.

Reference Type BACKGROUND
PMID: 21843614 (View on PubMed)

Perera PK, Li Y. Functional herbal food ingredients used in type 2 diabetes mellitus. Pharmacogn Rev. 2012 Jan;6(11):37-45. doi: 10.4103/0973-7847.95863.

Reference Type BACKGROUND
PMID: 22654403 (View on PubMed)

Thondre PS. Food-based ingredients to modulate blood glucose. Adv Food Nutr Res. 2013;70:181-227. doi: 10.1016/B978-0-12-416555-7.00005-9.

Reference Type BACKGROUND
PMID: 23722097 (View on PubMed)

Cheng DM, Kuhn P, Poulev A, Rojo LE, Lila MA, Raskin I. In vivo and in vitro antidiabetic effects of aqueous cinnamon extract and cinnamon polyphenol-enhanced food matrix. Food Chem. 2012 Dec 15;135(4):2994-3002. doi: 10.1016/j.foodchem.2012.06.117. Epub 2012 Jul 14.

Reference Type BACKGROUND
PMID: 22980902 (View on PubMed)

Pawar K, Thompkinson DK. Multiple functional ingredient approach in formulating dietary supplement for management of diabetes: a review. Crit Rev Food Sci Nutr. 2014;54(7):957-73. doi: 10.1080/10408398.2011.621039.

Reference Type BACKGROUND
PMID: 24499073 (View on PubMed)

Vinik AI. A medicinal food provides food for thought in managing diabetic neuropathy. Am J Med. 2013 Feb;126(2):95-6. doi: 10.1016/j.amjmed.2012.08.008. No abstract available.

Reference Type BACKGROUND
PMID: 23331432 (View on PubMed)

Stringer DM, Taylor CG, Appah P, Blewett H, Zahradka P. Consumption of buckwheat modulates the post-prandial response of selected gastrointestinal satiety hormones in individuals with type 2 diabetes mellitus. Metabolism. 2013 Jul;62(7):1021-31. doi: 10.1016/j.metabol.2013.01.021. Epub 2013 Feb 26.

Reference Type BACKGROUND
PMID: 23485142 (View on PubMed)

Welch RW, Antoine JM, Berta JL, Bub A, de Vries J, Guarner F, Hasselwander O, Hendriks H, Jakel M, Koletzko BV, Patterson CC, Richelle M, Skarp M, Theis S, Vidry S, Woodside JV; International Life Sciences Institute Europe Functional Foods Task Force. Guidelines for the design, conduct and reporting of human intervention studies to evaluate the health benefits of foods. Br J Nutr. 2011 Nov;106 Suppl 2:S3-15. doi: 10.1017/S0007114511003606.

Reference Type BACKGROUND
PMID: 22129662 (View on PubMed)

Jenkins DJ, Kendall CW, Banach MS, Srichaikul K, Vidgen E, Mitchell S, Parker T, Nishi S, Bashyam B, de Souza R, Ireland C, Josse RG. Nuts as a replacement for carbohydrates in the diabetic diet. Diabetes Care. 2011 Aug;34(8):1706-11. doi: 10.2337/dc11-0338. Epub 2011 Jun 29.

Reference Type BACKGROUND
PMID: 21715526 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.ccarm.ca

Canadian Centre for Agri-Food Research in Health and Medicine

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

B2014:041

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effects of Barley on Glucose Control
NCT02367989 ACTIVE_NOT_RECRUITING NA
The Fruit and Vegetable Prescription Program Study
NCT04597957 COMPLETED EARLY_PHASE1
Healthy Aging Through Functional Food
NCT02095873 COMPLETED PHASE1/PHASE2